Kevin D’Amour

Kevin D’Amour

Company: Stemson Therapeutics LLC

Job title: Chief Scientific Officer


Overcoming Weaknesses of Current In Vitro Models using Novel In Vivo Approaches 12:00 pm

Investigating key factors contributing to tumorigenesis in iPSCs to identify areas in need of greater attention during cell reprogramming and differentiation Employing in vitro and in vivo models to assess the tumorigenic potential of iPSC-derived cells, facilitating the selection of safer cell lines for therapeutic development Mitigating tumorigenicity risks throughout preclinical development, ultimately enhancing the safety and efficacy of iPSC-based therapiesRead more

day: Day One Track A AM

Industry Leaders’ Fireside Chat: Highlights & Hurdles from the Past Year 9:00 am

An interactive panel discussion from the industry leaders of the field to set the scene on the iPSC therapy space. Ask your questions live to understand the expert’s thoughts on key topics including: Highlighting and celebrating the big wins for iPSC community like recent start-ups and progress being made by US & Asian biopharma Considering…Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.